SanMelix Laboratories

Helping You Heal with Honey

SanMelix Laboratories

Helping You Heal with Honey

HOLLYWOOD, FL
Consumer Products
Our Goal is Simple, Faster and Healthier Healing

$120,782

raised
101
Investors
28
Days Left
$0.60
Price per Share
$6.56M
Valuation
Equity
Offering Type
$250
Min. Investment

$120,782

raised
101
Investors
28
Days Left
$0.60
Price per Share
$6.56M
Valuation
Equity
Offering Type
$250
Min. Investment

Reasons to Invest

First patent pending honey-based wound dressing formulations with Anticipated FDA microbial claim
U.S. Air force currently performing 510 (k) testing on wound dressing prototype
Our bioactive buckwheat honey products promote faster and healthier healing



Bringing faster healthier healing to all



Invest in SanMelix

Using the natural healing properties of Buckwheat honey, combined with our advanced bioactive enhancements, SanMelix has created a product that aids in the healing of acute, chronic and minor wounds. With pending patents, co-created by a renowned Harvard trained podiatric physician, SanMelix's advanced bioactive wound care products can be used in a host of settings and situations. We have created over-the-counter (OTC) skin care products such as ointments and creams designed to help in the healing of minor burns, scrapes, radiodermatitis and more. Our products will also be used for advanced wound care healing in hospitals and rehabilitation centers, by physicians through the use of dressings and ointments.


We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve the lives of patients and help speed up the healing process using the natural therapeutic properties that already exist in honey. Honey has been used in medicine since 8000 BC because of its unique healing properties and with our team of doctors and scientists, we have enhanced it through the use of broad-spectrum antimicrobials. Dr. Sabacinski developed the BEECure™ dressings to help prevent the dangerous side effects and adverse drug interactions that often arise with the use of predominantly synthetic pharmaceuticals. 


Dr. Sabacinski has been working in the wound care space for over thirty years, and he knows the patients’ needs for a product that encourages fast wound closure and provides protection from bacteria and infection. Our mission at SanMelix is to help people. We want to give caregivers, physicians, and the general public the ability to heal using a natural product that’s been used for centuries. At SanMelix, the proof is in the honey. 


With the funds raised through StartEngine, we plan to complete the testing on our products as well as prepare inventory. Our first product launch will be our OTC cosmetic line. We are in negotiations with a European company to license or purchase the CE Marked formulation for our first buckwheat honey skin care product and will use the funds to help complete this arrangement.

The entire population requires wound care



Sources:

*https://www.forbes.com/sites/genemarcial/2014/02/03/overlooked-advanced-wound-care-market-catches-attention-of-healthcare-analysts-investors/#5c53948c48a3

**https://www.grandviewresearch.com/industry-analysis/bioactive-wound-care-market

***https://medbroadcast.com/condition/getcondition/cuts-and-scrapes


But synthetic wound care products have issues


  • Potentially dangerous side effects can occur from entirely synthetic wound care products
  • There are environmental consequences to the manufacturing of chemical based products
  • There are multi drug resistant super infections such as MRSA and A. baumannii*
  • Skin grafts and skin substitutes require repeated application**
  • There are few effective therapies for radiotherapy, laser therapy and minor thermal burns***
  • Often severe wounds can result in amputations


Sources:

*https://www.reuters.com/investigates/special-report/usa-uncounted-cdc/  

**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775710/

***https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677297/

Using natural products we can solve them


  • SanMelix OTC formulations would be considered a first aid antibiotic/antiseptic/antimicrobial to treat minor cuts, scrapes and burns
  • In-vitro findings show that our honey formulations support the efficacy against MRSA and A. baumannii
  • Buckwheat honey reduces scarring and inflammation related to radiotherapy, laser therapy and minor thermal burns
  • Case studies illustrated accelerated healing and skin regeneration on severe limb threatening wounds
  • Need for fewer applications of skin grafts and skin substitute when honey dressings are applied to graft site
  • Studies have shown buckwheat honey has bactericidal activity against antibiotic-resistant pathogens*
  • Greener product in use and in manufacturing


Sources:

*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326189/ 

We create products using Buckwheat Honey

We are focusing on the unique medicinal properties of Buckwheat Honey for tissue regeneration and accelerated healing. Our bioactive buckwheat honey formulations demonstrate intrinsic healing activity with anti-microbial additives to prevent infection. Dr. Sabacinski co-invented 3 patent pending natural Buckwheat Honey BEECure™ medical devices which demonstrated superior clinical outcomes. Studies have proven that buckwheat honey has superior medicinal properties to Manuka honey and other natural remedies. Our products also have higher standardization and broader spectrum anti-microbial activity allowing them to be used on a physician level. Buckwheat honey also has higher anti-inflammatory and anti-oxidant activities than other products currently being used. 


The anti-oxidant properties in Buckwheat honey assist in wound closure and help to stimulate the wound healing process. This means wounds are healing faster and better without the risk of further complications that could be a great hindrance to the lives of patients. The mix of Buckwheat honey with our patent pending formulations creates a microbial barrier to prevent life-threatening bacteria from penetrating through the dressing while it is in use. The nutrients in the honey help spur tissue regeneration because it contains large quantities of easily assailable sugars, amino acids, vitamins, specifically vitamin C. Our products are made to heal chronic and difficult to close wounds.

Our Products in Use

Our BEECure™ products can be used for a wide variety of skin irritations and advanced wound care. Because of the microbial barrier claim in our wound care dressings, they will be instrumental in the treatment and healing of:

  • Ulcers, diabetic and otherwise
  • Skin grafts
  • Burns
  • Trauma and triage
  • And more!

We are working in tandem with Trauma Insight, who has formed a CRADA with the Airforce, to perform the 510(k) performance and microbial barrier testing. On the battlefield, being able to dress injuries quickly and carefully while keeping bacteria out of the wound is of the utmost importance. Right now, there's an antibiotic-resistant infection that is affecting military personnel overseas. Our dressings create a barrier that will keep the wound clean even in the harshest of conditions.


The advanced wound care MGO dressing is currently in the testing phase, and being tested by the U.S. Air Force. The radiodermatitis cream is in the testing phase for the product and packaging. All other products have not yet been created.

Advanced Wound Care (AWC)

BEECure™ MGO wound dressings

BEECure™ IMelix wound dressings

BEECure™ BMelix wound dressings

Over The Counter (OTC)

BEECure™ RMelix (radiodermatitis)

BEECure ™ Skin Care

BEECure™ Minor Burns

BEECure™ DFU Cream

The difference is in the ingredients

Although manuka honey is the most commonly used honey-based wound treatment on the market, studies have shown that buckwheat honey has superior inherent healing properties when compared to manuka honey due to its higher anti-inflammatory and higher anti-oxidant activities.  In addition, SanMelix’s advanced wound care products have been fortified with antimicrobials to ensure a higher standardized and broader spectrum antibacterial activity. Our patent-pending formulations utilized in our AWC dressings permit SanMelix to launch the first bioactive honey dressing to make a microbial barrier claim in the U.S. Our bioactive dressing will be for any wound type of any depth and severity. The dressing will prevent biofilms from forming,  control wound odor, reduce pain and treatment time while being cost-effective and more environmentally sound. 


Additionally, there will be improved skin and tissue regeneration and debriding action. This prevents the necessity for excess skin grafts or skins substitutes, which run the added risk of infection or rejection. Studies have shown buckwheat honey has bactericidal activity against antibiotic-resistant pathogens.


The bottom line is that our enhanced Buckwheat honey dressings and ointments are making the lives of patients and doctors easier. We are here to assist in the healing process and make a painful experience as painless as possible. We have seen firsthand the need for such products as the ones we've been creating and know that our BEECure™ products are going to be a big step forward in changing the lives of many. 



Natural ingredients that reduce inflammation and rehydrate your skin

Securing powerful partnerships

Through our collaboration with our Contract Research Organization, Trauma Insight, we have been able to establish a collaboration with the Air Force in order to conduct pre-clinical research that will support the 510(k) product testing. Trauma Insight builds on the lessons learned from combat casualty care delivered on the battlefield in Afghanistan and Iraq.


We are looking to continue testing our advanced wound care products to obtain 510(k) pre-market clearance from the FDA and to continue prosecuting our pending patent formulation applications. We are in negotiations with a European company to distribute its existing buckwheat honey CE Mark products for radio-dermatitis and laser therapy induced skin reactions and secure our main authentic raw buckwheat honey supplier.


On top of this, we are negotiating with other GMPs to contract manufacture our skin care products. We will continue to test, research and expand our products utilizing world renown physicians and scientists.


We are thrilled about all that lies ahead for the SanMelix team and the effect our nature-based products will have on healing.

A team of experts

SanMelix is proud to have some of the most experienced and widely renowned minds behind our products. Dr. Kenneth Sabacinski has worked in the advanced wound care space for over thirty years. He is a podiatric physician who started his training at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. People come from all over the world to see him for treatment of limb and life-threatening wounds including diabetic-related foot ulcers.


In addition to co-founder Dr. Sabacinski, our medical team of experts includes Dr. Jason Green, D.O. Board Certified Dermatologist, and COL (ret) George E. Peoples, MD, FACS. Dr. Green is our Advisory Board Director and is currently performing product testing of our initial CE Mark skin care product for radiodermatitis. Dr. George Peoples is the founder of Trauma Insight. Through his military career as a staff surgeon at a level I trauma center and multiple combat deployments, Dr. Peoples has extensive trauma experience and has developed close relationships with some of the most prominent military and civilian trauma and critical care physicians in the country.


Diana Sabacinksi and John Kaufman also serve as directors. Diana has over 25 years of accounting experience across a swath of fields, as well as starting her career in a Big 4 CPA international accounting firm.  John Kaufman is the founder of InteSec Group Fla LLC. He also founded Be Power Tech Inc. and served as its Chairman, Director, co-patent holder, and consultant. Together, the directors boast business acumen and scientific prowess and along with partnerships with other leading researchers and scientists, SanMelix is proud to have such strong and exciting leaders at the helm.

Dr. Kenneth Sabacinski

Diana Sabacinksi

Bringing buckwheat honey's healing power to skin care

Our skin care product line will provide honey based ointment for a myriad conditions like radiodermatitis, rashes, acne and much more. We are currently in the testing phase, running skin irritation and comparative performance tests. Our initial skin care product will be regulated under the United States Federal Food, Drug, and Cosmetic Act. The FDA OTC monograph program will use the patent pending formulations while using already recognized FDA products to enhance our creams and ointments. 

BEECure™ products can be used for or as a(an):

  • Acne Treatment
  • Antiseptic Bandage
  • Diabetic foot cream
  • Burn Care Ointment
  • Radiodermatitis
  • Eczema
  • Eye drops
  • Eczemema
  • Diaper Rash
  • And more!

What people are saying

Help us improve lives

There are over 50 million reported cases globally of patients suffering from hard-to-close wounds. 15% of these are diabetic foot ulcers that eventually lead to amputation. SanMelix BEECure™ bioactive wound care products are here to treat everything from a minor scrape to a severe wound and everything in between. Using our unique enhanced Buckwheat honey formulations fortified with microbial barriers, we are treating all types of dermal afflictions by speeding up the healing process and reducing pain and the risk of infection. 


Honey is a product that's been used all throughout history as a healing and restorative agent, and we are harnessing its natural powers and using our years of scientific and medicinal studies to enhance it. We are regulating it to make it safe for hospital use, as well selling it OTC to the average consumer. Everyone should be able to experience the benefits of the BEECure™ Buckwheat honey products. 


Our customers will include the VA & DoD, medical supply distributors, physician networks, hospitals, SNFs as well as indirect sales channel for private label/ white label for OTC opportunities. We will market directly to OTC consumers through digital marketing and social media. We are capitalizing on a market that has been desperately in need of a natural and safe product that promotes healing and tissue growth among many other benefits. 


We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve patients' lives in need of healing with our innovative bioactive wound care and skin care products.

Offering Summary


Company

:

SanMelix Laboratories, Inc.

Corporate Address

:

1150 North 35th Avenue Suite 225, HOLLYWOOD, FL 33021

Offering Minimum

:

$9,999.60

Offering Maximum

:

$1,069,998.00

Minimum Investment Amount

(per investor)

:

$249.60











Terms


Offering Type

:

Equity

Security Name

:

Common Stock NV

Minimum Number of Shares Offered

:

16,666

Maximum Number of Shares Offered

:

1,783,330

Price per Share

:

$0.60

Pre-Money Valuation

:

$6,561,600.00











*Maximum subject to adjustment for bonus shares. See Bonus info below

Investment Bonuses

If you invest $500+, you will receive 5% bonus shares.

If you invest $1,000+, you will receive 10% bonus shares.

If you invest $2,500+, you will receive 15% bonus shares.

If you invest $5,000+, you will receive 20% bonus shares.

The 10% Bonus for StartEngine Shareholders

SanMelix Laboratories, Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 in StartEngine's own offerings.

StartEngine shareholders who invested $1,000 or more in any StartEngine offering will receive a 10% bonus on this offering. This means you will receive a bonus for any shares you purchase. For example, if you buy 100 shares of Common Stock NV at $0.60 / share, you will receive 110 Common Stock NV shares, meaning you'll own 110 shares for $60. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors received their countersigned StartEngine Crowdfunding Inc. subscription agreement.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
USD
USD
Cash And Cash Equivalents
USD
USD
Accounts Receivable
USD
USD
Short Term Debt
USD
USD
Long Term Debt
USD
USD
Revenues And Sales
USD
USD
Costs Of Goods Sold
USD
USD
Taxes Paid
USD
USD
Net Income
USD
USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Exciting News

23 minutes ago

Happy Monday, 

Hope you’ve had an amazing summer! We sure did, as we could not be more excited to inform you, our BEECure™ MGO Advanced Wound Care Dressing Patent Was Issued. The patent approval demonstrates the company’s commitment to using robust intellectual property rights to develop visionary consumer, business and medical solutions. This notable achievement allows us to move forward with important initiatives and to speak more openly about our dressings and formulations.  We welcome you to Help Us Heal Others. Please continue to share our story to your network.

Sincerely,

The SanMelix Team

Exciting Milestone Achieved

6 days ago

Dear Shareholders,

Thank you so much for being a part of our crowdfunding campaign! Thanks to you and many others, we reached our equity crowdfunding goal of $107k in under two months. We are in active fundraising mode and continue to build momentum, therefore we made the decision to extend our campaign. We encourage you to share this milestone with others as we believe we have an opportunity to have an important impact on the world. Thank you for your continuous support, and we look forward to the joint path ahead.

Sincerely,

Diana Sabacinski

CEO SanMelix Laboratories, Inc.

Notice of Material Change in Offering

8 days ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SanMelix Laboratories offering. Here's an excerpt describing the specifics of the change:


Sanmelix has has increased their maximum funding goal.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

15 days ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

An In-Depth Article by Health Journal on our Business

25 days ago

We're proud to announce that since launching  our equity crowd-funding campaign in June to help propel BEECure forward, it quickly caught the attention of the publisher at Health Journal.  This award winning publishing company has designed successful marketing and public relations solutions for hundreds of clients. They recently published an editorial featuring SanMelix and our equity crowdfunding campaign. It's a detailed look at our business and what we're looking to achieve. Check out the article at here

 


 

Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}